Phaseline

Companies › Elgan Pharma

Elgan Pharma: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Gastroenterology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ELGN-2112
Human insulin [rDNA]
INSPhase 3Intestinal MalabsorptionJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05904626ELGN-2112Phase 2Intestinal MalabsorptionGastroenterologyJun 2027
NCT05670951ELGN-2112Phase 3Intestinal MalabsorptionGastroenterologyNov 2027

Targets

INS (1)

Companies with the same targets

Gateway Institute for Brain Research Gan & Lee Pharmaceuticals. Portal Diabetes

Companies built like this

Cinclus Pharma Holding Norgine Green Cross Wellbeing Inventiva Pharma Dr. Falk Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.